A federal jury has found that Teva must pay GlaxoSmithKline $235 million in a carve-out patent case over heart drug Coreg.
Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.
Scientific progress is leading to effective—but sometimes expensive—new treatments. Learn how value-based contracting could be the solution to pay for these…
Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.
Seqirus said it has achieved an industry first by producing a cell-based influenza vaccine on a commercial scale using a virus grown in cells.
Biopharma and its investors are breathing a sigh of relief on reports of the White House's drug pricing plans.
It’s a two-fer for McCann Health. The agency won Cannes Lions Health network advertising agency of the year for the second year in a row.
Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
A new Supreme Court decision could throw into question $300 million in talc verdicts against Johnson & Johnson.
Mylan, which already has a low tax rate by being based in the Netherlands, has cut it into the single digits by investing in refined coal plants.
After scoring impressive numbers with its science-focused TV ad, Pfizer is preparing to launch another next month starring one of its own scientists.